Alpha Cognition Inc.
6.57-0.03 (-0.46%)
Oct 29, 4:00:01 PM EDT · NasdaqCM · ACOG · USD
Key Stats
Market Cap
137.33MP/E (TTM)
-Basic EPS (TTM)
-1.59Dividend Yield
0%Recent Filings
8-K
Auditor switch post-relocation
Alpha Cognition Inc. announced the resignation of its auditor Manning Elliott on October 10, 2025, due to licensing issues after relocating its headquarters from Canada to Texas. The company promptly engaged U.S.-licensed CBIZ CPAs as its new independent auditor, expecting no disruptions to financial reporting. No disagreements or reportable events marred the prior audits for 2023 and 2024. Transition smooths operations.
8-K
ATM offering up to $75M
Alpha Cognition Inc. signed an at-the-market offering agreement with H.C. Wainwright & Co. on August 22, 2025, enabling sales of up to $75.0 million in common shares at its discretion. Wainwright earns up to 3.0% commission on gross sales, executed via ordinary brokerage transactions on Nasdaq. The deal bolsters funding flexibility. No sales obligation exists.
10-Q
Q2 FY2025 results
Alpha Cognition kicked off revenue in Q2 FY2025 with $1.7M total, blending $1.6M from ZUNVEYL product sales and $81K licensing, up from zero last year while R&D costs dropped 67% y/y to $317K post-FDA nod. Yet SG&A ballooned 356% y/y to $6.5M fueling the commercial push, driving a $10.5M net loss—wider than 2024's $2.1M, mainly from $5.2M warrant liability hits. Cash sits at $39.4M after $8.2M operating burn, with no debt and FCF not disclosed in the 10-Q. Licensing deal closed January 2025 with CMS for $3M upfront (cash), granting Asia-Pacific rights and recognizing $2.5M goodwill-equivalent IP value over 20 years. Warrants remain a wild card.
8-K
Annual meeting approves incentives
Alpha Cognition Inc. held its 2025 annual stockholder meeting on June 19, approving a six-member board with all nominees elected, ratifying Manning Elliot LLP as auditors, and adopting the 2025 Stock Incentive Plan for equity awards like options and restricted stock. The plan empowers the compensation committee to align incentives with performance. No major disruptions noted. Yet, broker non-votes hit 4 million shares.
10-Q
Q1 FY2025 results
Alpha Cognition kicked off Q1 FY2025 with $2.9M in revenue, blending $347K from ZUNVEYL product sales and $2.6M from a fresh Asia-Pacific licensing deal, marking a sharp y/y jump from zero. Yet operating expenses climbed 31% y/y to $6.6M, fueled by a 54% surge in SG&A to $5.4M amid commercialization ramps, while R&D dipped 56% y/y to $408K as priorities shifted. This narrowed the net loss to $2.0M, or $0.13 per share—85% better than last year's $5.0M hit—thanks to a $1.1M gain on warrant liabilities and $471K interest income. Cash burned $2.0M in operations, leaving $45.6M on hand after repaying a related-party note; free cash flow not disclosed in the 10-Q. The CMS pact, closed January 2025 for a $3.0M upfront (royalties at 9%), eyes regulatory milestones up to $11M. Solid liquidity persists. Still, regulatory hurdles in new markets loom large.
IPO
Sector
Industry
ABOS
Acumen Pharmaceuticals, Inc.
2.26-0.03
ACIU
AC Immune SA
3.84+0.32
AGNPF
Algernon Pharmaceuticals Inc.
0.06+0.00
ALEC
Alector, Inc.
1.55+0.05
ALZN
Alzamend Neuro, Inc.
2.45+0.09
ANRO
Alto Neuroscience, Inc.
14.04+0.42
ATHE
Alterity Therapeutics Limited
4.70-0.06
CGTX
Cognition Therapeutics, Inc.
1.58-0.01
IGC
IGC Pharma, Inc.
0.40-0.01
NRSN
NeuroSense Therapeutics Ltd.
1.06-0.06